Shots:

• Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd- Persen- EuBiotic. The transaction is expected to be closed in Q1’20
• The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen Zentiva’s geographical footprint and complements generics and OTC portfolio
• Alvogen’s divestiture of its European business will allow its focus on development- growth and expansion in other therapeutic areas as it is currently focusing on biosimilars through its sister company- Alvotech

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Idnes